A glance of the recent development of 12 investment incubators of Viva Biotech

SHANGHAI, Dec.
1, 2022 /PRNewswire/ -- In the face of the ever-changing situation, technological innovation is still the eternal theme of the long-term development of biopharmaceutical enterprises, continuously injecting vitality into enterprises, and continuously promoting the "0 to 1" transformation of R&D and commercialization success
。 Recently, 12 investment incubators have achieved remarkable results and progress: Focus-X Therapeutics and Radiolink Pharma successfully reached an acquisition agreement; Aleta Biotherapeutics, Domain, Triumvira, Bichen Pharmaceutical, and Qiyu Biotech successfully advanced the R&D pipeline; Zizheng Biologics, Cybrexa, and Anji Pharmaceutical have reached important cooperation in their respective segments; DTx Pharma, HAYA Therapeutics, and Sochi Biology won awards one after another
.
Below, let's take a look at their developments
.

Focus-X Therapeutics, an investment incubation company by Viva Biotech, successfully reached an acquisition agreement with Radiolink Pharma

On November 29, 2022, Focus-X Therapeutics (hereinafter referred to as "Focus-X"), a nuclear drug company invested and incubated by Viva Biologics, successfully reached an acquisition agreement
with Radiolink Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as "Radiolink Pharma").
Under the terms of the Acquisition, Radiolink will pay Focus-X a total of $245 million in transaction consideration, including upfront payments and potential development, registration, sales milestone fees and royalties
for commercial sales.
The acquisition is expected to close
in the first quarter of 2023.
This is also another project that was acquired in the preclinical stage after Dogma and Totient of Via Investment Incubation, which once again verified the ability of Viva Investment team to explore projects and professional post-investment support
.

Focus-X, a company that develops targeted radiopharmaceuticals to treat cancer based on its proprietary peptide engineering technology, was led by Viva Biotech in its angel round
in the third quarter of 2020.
In addition to financial support, Viva Biotech also provided Focus-X with comprehensive incubation services to help it realize the transformation
from "concept to product".

Sozhi Biotech won the "Top Ten Overseas Talent Entrepreneurship Projects of Haichuanghui"

On November 28, Sochi Biotechnology, which was invested and incubated by Viva Biotech, was invited to participate in the 2022 Pudong New Area Innovation and Entrepreneurship Summit and stood out from more than 300 excellent projects and won the award honor of "Top Ten Overseas Talent Entrepreneurship Projects of Haichuanghui"
.
The company was co-sponsored
by the Shanghai Municipal Association for Science and Technology, the Organization Department of the Pudong New Area Party Committee, the Pudong New Area Science and Economic Commission, and the Zhangjiang Management Bureau of the Free Trade Zone Administrative Committee.
Sochi Biotech will continue to better integrate resources and talent advantages in the territory of biomedicine and artificial intelligence in Pudong New Area, and strive to accelerate innovative drug research and development projects
by introducing more professional talents.

Zizhan + Corning: Construction of an in vitro 3D model of CAR-NK cell infiltration of tumor extracellular matrix targeting to kill tumor cells

On November 22, Shanghai Zizhen Pharmaceutical Technology Co.
, Ltd.
("ZizhenBio"), which was invested and incubated by Viva Biologics, Corning Life Sciences and Yijingtong Optical Technology ("Olympus Life Sciences") jointly announced the establishment of the "Zizhen Biologics Drug Phenotyping Screening Platform Based on Complex Disease Models and Bioimaging"
.

The Generics Pharmaceutical Phenotyping Screening Platform will perfectly integrate Genea's complex disease modeling technology platform, Corning Life Sciences' high-quality biotechnology products and global experience, and Yijingtong Optics' superior bioimaging solutions to provide customers with the highest quality drug phenotypic screening services
.

Aleta Biotherapeutics announces that ALETA-001, a CAR-T cell therapy adapter, has been granted accreditation as an Innovation Passport

Recently, Aleta Biotherapeutics (Aleta), which is invested and incubated by Viva Biologics, announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted the company's pipeline ALETA-001 (CAR-T cell therapy adapter) an Innovation Passport (ILAP) for the treatment of patients with B-cell malignancies, Patients with non-Hodgkin lymphoma (NHL) and acute lymphoblastoma with leukemia (ALL), and patients
who do not respond or relapse after CD19 CAR T cell therapy.
ALETA-001 is expected to enter clinical phase in 2023 and is sponsored by Cancer Research UK's Centre for Drug Development and conducts a Phase 1/2a clinical trial
.

Cybrexa and Exelixis entered into an exclusive partnership to provide Exelixis with the rights to acquire CBX-12

November 1, Alameda, California and New Haven, Connecticut, Exelixis and Cybrexa Therapeutics ("Cybrexa"), which is invested and incubated by Viva Biotech, announced that they have entered into an exclusive partnership agreement to provide Exelixi with the acquisition of
CBX-12 (alphalex exatecan).
。 Under the cooperation agreement, Exelixis will pay Cybrexa an upfront payment of $60 million in exchange for the acquisition of CBX-12 rights following the publication of Phase I clinical results and to fund
Cybrexa to advance the agreed development and manufacturing program.
Cybrexa is also expected to receive additional benefits of up to $642.
5 million, including development, manufacturing and commercial milestone payments, as well as the purchase of
CBX-12 after evaluating pre-specified clinical data.

CBX-12 is a first-in-class peptide conjugate (PDC) in clinical research that delivers a highly effective second-generation topoisomerase I inhibitor exatecan directly to tumor cells through alphalex technology, increasing the effectiveness of topoisomerase I inhibitors and reducing toxicity
.

DTx Pharma and HAYA Therapeutics were selected for Clarivate's new RNA Technology Companies to Watch report

On October 25, London, England, Clarivate released a new report - RNA Technology Companies to Watch
.
The report comprehensively analyzes RNA companies' drug benefits, financing, R&D activities, etc.
, revealing emerging RNA outstanding companies
in the medical field.
A total of 7 emerging innovative RNA technology companies were selected this time, including DTx Pharma and HAYA Therapeutics, which were invested and incubated by Viva Biotech
.

In addition, Haya Therapeutics won the Seed of the Year Award at the recent European Lifestars Awards at LSX
.

Domain's EP4R antagonist DT-9081 for the treatment of solid tumors was approved for clinical use

On October 19, Strasbourg, France & Montreal, Canada, Domain Therapeutics ("Domain"), a biopharmaceutical company invested and incubated by Viva Biologics that focuses on the research and development of new drugs targeting G protein-coupled receptor (GPCR) immuno-oncology, announced that its first fully in-house IO drug candidate, DT-9081, It has passed the Clinical Trial Application (CTA) of the French National Agency for the Safety of Medicines and Health Products (ANSM)
and the Belgian Agency for Medicines and Healthcare Products (AFMPS).
With the approval of this clinical trial, Domain is about to open a phase I clinical trial and is expected to complete the dosing
of the first patient by the end of this year.

Anji and PHP have established a strategic cooperation to jointly tackle high-incidence diseases

On October 19, Cambridge and New York, Massachusetts, Anji Pharmaceuticals and Population Health Partners, invested and incubated by Viva Biologics, officially announced a strategic cooperation, and the two teams will work closely together to overcome the problem
of high incidence of human diseases.

Since the beginning of the partnership between Agengen and PHP, recent efforts have focused on accelerating the development of
Agen's two major clinical pipelines.
ANJ900 (Metformin Delayed Release New Dosage Form) is undergoing Phase 3 clinical trials to make metformin safe for use in patients
with type 2 diabetes complicated by moderate to severe chronic kidney disease (CKD).
ANJ908 (pradigastat) is an innovative DGAT1 inhibitor that has successfully completed Phase 2 clinical trials (NCT04620161)
in patients with chronic functional constipation.

Triumvira will expand cell therapy capacity at its South San Francisco facility and previously announced initial Phase 1/2 clinical data for TAC01-HER2

On October 19, Triumvira Immunologics ("Triumvira"), a clinical-stage company focused on the development of novel, targeted autologous and allogeneic TCR-T cell therapies focused on the treatment of solid tumors, invested and incubated by Viva Biologics, announced a multi-year agreement with AmplifyBio.
It will use its facility in South San Francisco, California to manufacture in-line cell therapy drug candidates
.
Triumvira expects the facility to be fully operational
in 2023.

Previously, in September, Triumvira published initial Phase 1/2 clinical data
for TAC01-HER2 for the treatment of HER2-positive solid tumors at ESMO 2022.
The data showed that TAC01-HER2 was well tolerated in both dosing groups, and early signals of clinical activity were observed in the group with a disease control rate of 75%, including one case of partial remission
.

BICHEN Pharmaceutical's brain MEK inhibitor ABM-168 was approved by the US FDA and Dr.
Yang Zandong was appointed as the Chief Medical Officer

October 12, Shanghai, China/San Diego, USA, ABM Therapeutics, a small molecule drug development company invested and incubated by Viva Biologics and focusing on breaking through the blood-brain barrier, announced that its self-developed brain-accessible MEK1/2 inhibitor ABM-168 has been approved by the US Food and Drug Administration (FDA) for new drug clinical trial (IND
).
This is also the second self-developed drug
approved for clinical trials in the United States after ABM-1310.
With this clinical approval, BICHEN's upcoming Phase I clinical trial will recruit patients with advanced solid tumors, especially complicated brain metastases or primary brain tumors, aiming to explore the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity
of ABM-168 in such patients.

Previously, on October 10, BICHEN announced the appointment of Dr.
Zane Yang, M.
D.
as the company's chief medical officer (CMO) to fully lead and manage BICHEN's global clinical development affairs, formulate and implement clinical development strategies, and participate in the planning and implementation
of the company's overall business and development strategies.
Dr.
Yang has a strong professional and academic background, rich experience in clinical R&D and management
.

Q-1801 project was approved by the US FDA

On September 24, Qiyu Biotechnology, which was invested and incubated by Viva Biologics, announced that its self-developed Q-1801 project has obtained the US FDA clinical trial approval notice, and is in the process of China IND application
.
Developed by Qiyu Biologics using its antibody engineering technology platform, Q-1801 is the world's first bispecific antibody
targeting both SIRPα and PD-L1.
Q-1801 is also the second clinical application project of Qiyu Biotechnology, which further demonstrates the independent research and development and innovation capabilities
of Qiyu Biotechnology.